Cargando…

Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice

Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Jha, Aruni, Doyle-Eisele, Melanie, Revelli, David, Carnelley, Trevor, Barker, Douglas, Kodihalli, Shantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860936/
https://www.ncbi.nlm.nih.gov/pubmed/36680164
http://dx.doi.org/10.3390/v15010123
_version_ 1784874715862532096
author Jha, Aruni
Doyle-Eisele, Melanie
Revelli, David
Carnelley, Trevor
Barker, Douglas
Kodihalli, Shantha
author_facet Jha, Aruni
Doyle-Eisele, Melanie
Revelli, David
Carnelley, Trevor
Barker, Douglas
Kodihalli, Shantha
author_sort Jha, Aruni
collection PubMed
description Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC(0–∞) and Cl. AUC(0–last) increased and mean residence time, T(1/2), and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure.
format Online
Article
Text
id pubmed-9860936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98609362023-01-22 Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice Jha, Aruni Doyle-Eisele, Melanie Revelli, David Carnelley, Trevor Barker, Douglas Kodihalli, Shantha Viruses Communication Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC(0–∞) and Cl. AUC(0–last) increased and mean residence time, T(1/2), and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure. MDPI 2022-12-30 /pmc/articles/PMC9860936/ /pubmed/36680164 http://dx.doi.org/10.3390/v15010123 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Jha, Aruni
Doyle-Eisele, Melanie
Revelli, David
Carnelley, Trevor
Barker, Douglas
Kodihalli, Shantha
Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
title Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
title_full Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
title_fullStr Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
title_full_unstemmed Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
title_short Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
title_sort pharmacokinetic and pharmacodynamic effects of polyclonal antibodies against sars-cov2 in mice
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860936/
https://www.ncbi.nlm.nih.gov/pubmed/36680164
http://dx.doi.org/10.3390/v15010123
work_keys_str_mv AT jhaaruni pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice
AT doyleeiselemelanie pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice
AT revellidavid pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice
AT carnelleytrevor pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice
AT barkerdouglas pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice
AT kodihallishantha pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice